BNGO Bionano Genomics
- 0.9957
- +0.0757+8.23%
Bionano Genomics News
Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2024 Earnings Call Transcript
BioNano Genomics (BNGO) Gets a Buy From Scotiabank
Q1 2024 Bionano Genomics Inc Earnings Call
Bionano Genomics Inc (BNGO) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...
Bionano Announces Series of Major Advancements to Its Suite of Computational Tools for Comprehensive Cancer Analysis
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These ad
Bionano Genomics, Inc. (BNGO) Q1 2024 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Q1 2024 Earnings Call Transcript
Bionano Genomics (BNGO) Q1 2024 Earnings Call Transcript
Bionano Reaffirms FY24 Revenue Guidance $37M-$41M
Bionano Reaffirms FY24 Revenue Guidance $37M-$41M
Bionano Genomics up 7% on Narrowed Quarterly Loss, Revenue Beat
Bionano Genomics Q1 2024 GAAP EPS $(0.60) Beats $(0.65) Estimate, Sales $8.769M Beat $8.492M Estimate
Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.65) by 7.69 percent. This is a 51.22 percent increase over losses of $(1.
10-Q: Quarterly report
Bionano Genomics 1Q Rev $8.8M >BNGO
Bionano Genomics 1Q Rev $8.8M >BNGO
Bionano Genomics Sees 2Q Rev $7.8M-$8.2M >BNGO
Bionano Genomics Sees 2Q Rev $7.8M-$8.2M >BNGO
Press Release: Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress
Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress -- Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023 -- Total installed ba
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern
Bionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the RBC C
Bionano Announces Publication Showing OGM's High Resolution Structural Variation Detection In Cancer Validated By Cas9-Directed Nanopore Sequencing
Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM)
Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health
Bionano Genomics (BNGO) said Wednesday it has entered into an original equipment manufacturing partnership with Hangzhou Diagens Biotechnology to commercialize cytogenetic workflow to support reproduc
Bionano Enters OEM Partnership With Diagens To Commercialize A Clinical Cytogenetic Analysis That Combines OGM And Artificial Intelligence
Bionano Enters OEM Partnership With Diagens To Commercialize A Clinical Cytogenetic Analysis That Combines OGM And Artificial Intelligence
Bionano Announces Publication Showing That OGM Detects Over 1250 Structural Variants, Including 56 Gene Fusions, In Pediatric Leukemia That Were Missed By Whole Genome Sequencing
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping (OGM) to search for clinically and biologically rel
Analysis
Price Target
No Data
